Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

NATerminatedINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Type 2 DiabetesObesity
Interventions
DEVICE

EndoBarrier

Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point

PROCEDURE

Sham Procedure

Endoscopic evaluation but no device placement

Trial Locations (25)

10003

Beth Israel Medical Center, New York

20782

MedStar Health Research Institute, Hyattsville

27599

University of North Carolina, Chapel Hill

30303

Emory University, Atlanta

35294

University of Alabama at Birmingham, Birmingham

37909

Endocrinology Consultants of East Tennessee & Gastrointestinal Associates, Knoxville

40218

Kentucky Research Group, Louisville

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic Minnesota, Rochester

59101

Billings Clinic, Billings

60208

Northwestern University, Chicago

63110

Washington University, St Louis

72205

Little Rock Diagnostic Center (LRDC), Little Rock

75230

Dallas Diabetes, Dallas

77030

The Methodist Hospital Research Institute, Houston

80045

University of Colorado/ Anschutz Health & Wellness Center, Aurora

85259

Mayo Clinic Arizona, Scottsdale

90048

Cedars-Sinai Medical Center, Los Angeles

94305

Stanford University School of Medicine, Stanford

97232

Legacy Research Institute, Portland

70112-2699

Tulane University Health Sciences Center, New Orleans

02114

Massachusetts General Hospital, Boston

02118

Boston Medical Center, Boston

75390-7170

UT Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Morphic Medical Inc.

INDUSTRY